Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic InfluenzaCompleted
NCT06179446Phase 1Updated Feb 23, 2026
Sponsor: Pfizer
Grippe · Influenza · Vaccines
United States
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility StudyRecruiting
NCT06016387Phase 2Updated Feb 23, 2026
Sponsor: Sunnybrook Health Sciences Centre
HER2-positive Breast Cancer · LMD
Canada
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.Terminated
NCT06546553Phase 1Updated Feb 23, 2026
Sponsor: Pfizer
Neoplasms · Non-small-cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck · Renal Cell Carcinoma
United States
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerRecruiting
NCT07193394Phase 2Updated Feb 23, 2026
Sponsor: Institut Curie
Metastatic Breast Cancer ( HER2 Negative) · Unresectable Breast Cancer
France
A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy AdultsCompleted
NCT07423286Phase 1Updated Feb 20, 2026
Sponsor: Pfizer
Healthy Adult Participants
United States
ATTR-CM: A Multi-country, Non-interventional Disease RegistryActive Not Recruiting
NCT06651073N/AUpdated Feb 19, 2026
Sponsor: Pfizer
Transthyretin Amyloid Cardiopathy
Taiwan
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid TumorsTerminated
NCT05233436Phase 1Updated Feb 19, 2026
Sponsor: Pfizer
Advanced Solid Tumors · Gastric Cancer · Gastroesophageal Junction Cancer · Urothelial Cancer
United States, Japan
Axitinib and Nivolumab for the Treatment of Mucosal MelanomaRecruiting
NCT05384496Phase 2Updated Feb 18, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Mucosal Melanoma
United States
Psoriatic Arthritis and Psoriasis Treatment Decision AidCompleted
NCT03737045NAUpdated Feb 17, 2026
Sponsor: University of Pennsylvania
Psoriatic Arthritis · Psoriasis
United States
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the BrainActive Not Recruiting
NCT05892068Phase 2Updated Feb 13, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer
United States
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsSuspended
NCT03065062Phase 1Updated Feb 13, 2026
Sponsor: Dana-Farber Cancer Institute
Lung Cancer Squamous Cell · Solid Tumors · Head & Neck Cancer · Pancreatic Cancer
United States
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic LeukemiaTerminated
NCT03913559Phase 2Updated Feb 12, 2026
Sponsor: St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia
United States
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive Not Recruiting
NCT02947685Phase 3Updated Feb 12, 2026
Sponsor: Alliance Foundation Trials, LLC.
HER-2 Positive Breast Cancer · Estrogen Receptor Positive Breast Cancer
United States, Australia, France, Germany, Italy +3 more
PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC TrialActive Not Recruiting
NCT02624973Phase 2Updated Feb 12, 2026
Sponsor: Haukeland University Hospital
Breast Cancer
Norway
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerCompleted
NCT03170206Phase 1Updated Feb 12, 2026
Sponsor: Dana-Farber Cancer Institute
Lung Cancer
United States
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast CancerCompleted
NCT02499146Phase 1Updated Feb 11, 2026
Sponsor: Pfizer
Advanced Breast Cancer
China
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to TreatmentCompleted
NCT05014412Phase 2Updated Feb 10, 2026
Sponsor: Pfizer
Multiple Myeloma
United States, Japan, Taiwan, United Kingdom
Korea Post Marketing Surveillance (PMS) Study of VizimproCompleted
NCT04721106N/AUpdated Feb 10, 2026
Sponsor: Pfizer
Lung Neoplasms
South Korea
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerActive Not Recruiting
NCT05909397Phase 3Updated Feb 10, 2026
Sponsor: Pfizer
Breast Cancer
United States, Australia, Brazil, China, Hungary +5 more
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)Active Not Recruiting
NCT05548127Phase 1, Phase 2Updated Feb 10, 2026
Sponsor: Pfizer
Breast Cancer
United States, Canada, Italy, Spain
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.Recruiting
NCT06015542Phase 2Updated Feb 10, 2026
Sponsor: Thomas Lund
Multiple Myeloma
Denmark
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming SevereCompleted
NCT07072793N/AUpdated Feb 9, 2026
Sponsor: Pfizer
COVID-19 (Coronavirus Disease 2019)
United States
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in KoreaCompleted
NCT06593587Phase 3Updated Feb 9, 2026
Sponsor: Pfizer
Respiratory Syncytial Virus
South Korea
A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of MalnutritionTerminated
NCT07086664Phase 1Updated Feb 6, 2026
Sponsor: Pfizer
Healthy Volunteers
United States, Canada, Japan
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With ObesityCompleted
NCT06717425Phase 2Updated Feb 6, 2026
Sponsor: Pfizer
Obesity
United States, Canada, Poland

Previous page Next page